Pharma Trademark Wars: Why the Bombay High Court Prioritized Public Safety Over Dual Registration in the 'OCTRIDE' vs. 'OTIDE' Passing Off Battle.
In the high-stakes world of pharmaceutical branding, a single letter can be the difference between a life-saving treatment and a dangerous medical error. A recent decision by the Bombay High Court in the case of Sun Pharma Laboratories Limited vs. United Biotech Private Limited offers a masterclass in the nuances of trademark law, specifically where rival medicinal products are derived from the same generic molecule. The judgment serves as a critical reminder that in the pharmaceutical sector, the "rules of the game" are significantly more stringent than in ordinary commerce.
The Paradox of Dual RegistrationOne of the most striking aspects of this case is the conflict between two registered trademark holders. Sun Pharma (using "OCTRIDE") and United Biotech (using "OTIDE") both held valid registrations. Under Section 28(3) of the Trade Marks Act, 1999, one registered proprietor cannot typically sue another for infringement. The court reaffirmed that to overcome this statutory hurdle at an interim stage, a plaintiff must show that the defendant's registration is ex-facie illegal or fraudulent—a threshold so high it must "shock the conscience of the court".
While Sun Pharma could not immediately dismantle the validity of the "OTIDE" registration, the court highlighted a vital escape hatch: the common law action of passing off. This reminds practitioners that registration is a shield, but it is not an absolute cloak of invincibility against claims of unfair competition.
The "Bare Possibility" Standard in PharmaPerhaps the most impactful takeaway is the court's application of the "exacting judicial scrutiny" test for medicinal products. Unlike consumer goods where a "likelihood of confusion" is the standard, pharmaceutical trademarks are judged on the "bare possibility" of confusion. The court noted that because medicines are often prescribed over the phone or written in illegible handwriting, the margin for error must be zero.
"In respect of medicinal products it was held that exacting judicial scrutiny is required if there was a possibility of confusion over marks on medicinal products because the potential harm may be far more dire than that in confusion over ordinary consumer products."
The court found that "OCTRIDE" and "OTIDE" were phonetically too close, especially when considering hurried utterances in a busy pharmacy or rural clinical setting. This reinforces the principle that even if a mark is derived from a generic molecule (in this case, Octreotide Acetate), the manufacturer has an affirmative duty to create "sufficient distance" from existing brands.
Delay is Not Always AcquiescenceA common defense in trademark litigation is that the plaintiff waited too long to sue, thereby "acquiescing" to the defendant's use. United Biotech argued that Sun Pharma had known of their product since at least 2010 through medical journals. However, the court drew a sharp line between mere delay and legal acquiescence. Relying on Supreme Court precedents, the judge noted that for a plaintiff to lose their rights, there must be a "positive act" of encouragement toward the defendant.
The court observed that simply "sitting by" or failing to notice a competitor in a medical journal does not equate to giving them a green light. This is a significant win for brand owners who may not have the resources to monitor every corner of the market at all times.
The Weight of Commercial RealityFinally, the judgment underscores the importance of "the numbers". While both parties claimed long-term use, the court looked closely at the sales turnover at the time the conflict began. In 2006, Sun Pharma’s turnover was approximately Rs 7 crores, while the defendant’s was a mere Rs 27 lakhs. This "great divide" in commercial presence helped the court determine where the "balance of convenience" lay. It serves as a practical lesson: in equity-based reliefs like injunctions, the actual market footprint often speaks louder than the date on a registration certificate.
ConclusionThe Sun Pharma ruling reinforces a protective stance toward public health. By prioritizing phonetic similarity and the "bare possibility" of confusion over the technicalities of dual registration, the Bombay High Court has signaled that in the pharmacy aisle, consumer safety is the ultimate trademark. For businesses, the message is clear: when naming a drug, being "close enough" to the generic name is fine, but being "too close" to a competitor is a recipe for litigation.
Case: Sun Pharma Laboratories Limited v. United Biotech Private Limited
Law: Trade Marks Act, Code of Civil Procedure, Drugs and Cosmetics Act.
Citation: 2026:BHC-OS:11436
Decision Date: 04-05-2026